NASDAQ:BRBI BR Biopharma (BRBI) Stock Price, News & Analysis $11.72 +0.49 (+4.31%) As of 03:28 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsOwnershipSEC FilingsShort Interest About BR Biopharma Stock (NASDAQ:BRBI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BR Biopharma alerts:Sign Up Key Stats Today's Range$11.24▼$11.2450-Day Range$9.13▼$12.1352-Week Range$9.09▼$67.01Volume310 shsAverage Volume649 shsMarket Capitalization$138.47 millionP/E Ratio146.56Dividend Yield3.58%Price TargetN/AConsensus RatingSell Company Overview BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil. Read More BR Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreBRBI MarketRank™: BR Biopharma scored higher than 20% of companies evaluated by MarketBeat, and ranked 765th out of 837 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBR Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBR Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about BR Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BR Biopharma is 143.70, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.07.Price to Earnings Ratio vs. SectorThe P/E ratio of BR Biopharma is 143.70, which means that it is trading at a more expensive P/E ratio than the Finance sector average P/E ratio of about 25.31.Price to Book Value per Share RatioBR Biopharma has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of BR Biopharma has been sold short.Short Interest Ratio / Days to CoverBR Biopharma has a short interest ratio ("days to cover") of 1.15, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BR Biopharma has recently decreased by 65.42%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipBR Biopharma is a leading dividend payer. It pays a dividend yield of 3.76%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthBR Biopharma does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of BR Biopharma is 525.00%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about BR Biopharma's dividend. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for BR Biopharma this week, compared to 1 article on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BR Biopharma insiders have not sold or bought any company stock.Percentage Held by InstitutionsBR Biopharma has minimal institutional ownership at this time.Read more about BR Biopharma's insider trading history. Receive BRBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BR Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BRBI Stock News HeadlinesContrasting BR Biopharma (BRBI) & Its RivalsSeptember 21 at 8:59 AM | americanbankingnews.comFinancial Survey: BR Biopharma (BRBI) & The CompetitionSeptember 20 at 4:14 AM | americanbankingnews.comPass by August 7… or wait until 2027?Last month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was. Federal regulators granted conditional approval to World Liberty Trust Company… a nationally chartered trust bank tied to the Trump family's crypto venture. Most investors still haven't processed what that means. This bank exists to do one thing. Issue, redeem, custody and back USD1… the stablecoin that has now crossed $4 billion in circulation. The bank isn't operating yet. There are conditions to satisfy first… capital minimums, an audit manager, a sign-off on the business plan. Which means the money hasn't moved yet.September 22 at 1:00 AM | Crypto 101 Media (Ad)BR Biopharma (BRBI) & Its Rivals Head-To-Head ComparisonSeptember 19 at 4:29 AM | americanbankingnews.comSee More Headlines BRBI Stock Analysis - Frequently Asked Questions How have BRBI shares performed this year? BR Biopharma's stock was trading at $14.75 on February 17, 2026. Since then, BRBI stock has decreased by 22.0% and is now trading at $11.4990. How were BR Biopharma's earnings last quarter? BR Biopharma, Inc. (NASDAQ:BRBI) released its quarterly earnings data on Tuesday, June, 30th. The company reported $0.09 earnings per share for the quarter. The business had revenue of $25.13 million for the quarter. How do I buy shares of BR Biopharma? Shares of BRBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings6/30/2026Record date for 9/4 Dividend8/17/2026Ex-Dividend for 9/4 Dividend8/17/2026Dividend Payable9/04/2026Today9/22/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorFinance Industry Capital Markets Sub-IndustryInvestment Banking & Brokerage Current SymbolNASDAQ:BRBI CIK2058601 Webwww.brpartners.com.br Phone55-11-3704-1000FaxN/AEmployees188Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio146.36 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.87 Quick Ratio0.87 Sales & Book Value Annual Sales$2.23 billion Price / Sales0.06 Cash Flow$2.98 per share Price / Cash Flow3.94 Book Value$11.88 per share Price / Book0.99Miscellaneous Outstanding Shares11,810,000Free FloatN/AMarket Cap$138.47 million OptionableN/A BetaN/A 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:BRBI) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our PartnersThe drone firm the Pentagon chose for next-gen defenseOne Nasdaq-listed drone company already supplies the US Army, Air Force, and Navy with mission-ready drone sys...Tomorrow Investor | SponsoredPass by August 7… or wait until 2027?Last month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was...Crypto 101 Media | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | Sponsored“Elon Is Not Showing This Publicly, But I Saw It”Elon Musk quietly filed a patent for a new AI invention while attention focused on the SpaceX IPO. Jeff Brown,...Brownstone Research | SponsoredA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...Stansberry Research | SponsoredChina's dominance in rare earth processing sparks new defense rulesOn January 1, 2027, new Pentagon rules tighten sourcing restrictions on critical minerals tied to foreign adve...The Tomorrow Investor | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BR Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BR Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
